bioXXmed AG (FRA:T5O) DeferredTaxAndRevenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T5O bioXXmed AG FRA:T5O
45 GF Score
Price €0.95
GF Value €10.54
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioXXmed AG DeferredTaxAndRevenue?

bioXXmed AG FRA:T5O 45 DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:T5O with a GF Score™ of 45/100 and a GF Value™ of €10.54 (Possible Value Trap). The stock has 3 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

bioXXmed AG's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

bioXXmed AG DeferredTaxAndRevenue Related Terms

bioXXmed AG DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for bioXXmed AG's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioXXmed AG DeferredTaxAndRevenue Chart

bioXXmed AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

bioXXmed AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:T5O
45GF Score
bioXXmed AG FRA:T5O
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €0.00 Mil mean?
bioXXmed AG (FRA:T5O) has a DeferredTaxAndRevenue of €0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on bioXXmed AG.
Is bioXXmed AG's DeferredTaxAndRevenue too high?
bioXXmed AG's current DeferredTaxAndRevenue is €0.00 Mil. Overall, bioXXmed AG has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's DeferredTaxAndRevenue compare to VRTX and REGN?
bioXXmed AG's DeferredTaxAndRevenue of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on bioXXmed AG. bioXXmed AG's current DeferredTaxAndRevenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (FRA:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €10.54, compared to a current price of €0.95 — trading 91% below its estimated fair value. The current DeferredTaxAndRevenue is €0.00 Mil. bioXXmed AG's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For bioXXmed AG (FRA:T5O), the current DeferredTaxAndRevenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioXXmed AG (FRA:T5O) Overvalued in 2026?

Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued. The current stock price of €0.95 is trading 91% below its estimated GF Value™ of €10.54. GuruFocus considers bioXXmed AG to be Possible Value Trap.

Key valuation signals for FRA:T5O:

  • DeferredTaxAndRevenue: €0.00 Mil
  • GF Value™: €10.54 vs. price of €0.95 (91% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the FRA:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioXXmed AG Business Description

Other Exchanges T5O:Germany
Address Riedstrasse 2, Darmstadt, HE, DEU, 64295
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
45GF Score

Get the complete analysis for FRA:T5O

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€10.54
GF Value